Summary & Overview
CPT 0622U: TruD MDS Major Depressive Disorder Epigenetic Assay
CPT code 0622U designates a proprietary laboratory analysis — the TruD MDS Major Depressive Disorder test from TruDiagnostic™ Inc. This epigenetic assay evaluates DNA methylation at more than 20,000 sites from a whole blood sample and uses an algorithm to produce a positive or negative risk result for major depressive disorder. As a PLA code, 0622U is specific to a single manufacturer’s test, which affects coding, billing, and coverage considerations nationwide.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national perspective on the clinical purpose of the test, how it is categorized for billing, and the implications of PLA status on payer engagement. The publication outlines available benchmarks and coverage patterns where available, highlights relevant policy considerations for proprietary laboratory tests, and summarizes the clinical context for use in psychiatry.
This resource does not provide state-specific guidance. Data not provided in the input (including specific payer policies, modifiers, taxonomies, ICD-10 pairings, and service line details) are noted as unavailable and are not fabricated.
Billing Code Overview
CPT code 0622U is a Proprietary Laboratory Analyses (PLA) code that applies to a single, manufacturer-specific laboratory test: TruD MDS Major Depressive Disorder from TruDiagnostic™ Inc. The test analyzes DNA methylation at more than 20,000 sites using a whole blood sample and reports results via an algorithm as a positive or negative risk for major depressive disorder.
Service type: Molecular diagnostic laboratory test (proprietary epigenetic assay)
Typical site of service: Clinical laboratory or reference lab, using a whole blood specimen
Data not available in the input for payers, modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to a psychiatry clinic or primary care office with symptoms consistent with major depressive disorder (MDD) such as persistent low mood, anhedonia, sleep disturbance, appetite change, and functional decline despite initial treatment or when objective risk stratification is desired. The ordering clinician (psychiatrist, psychiatric nurse practitioner, or primary care physician) documents the indication for objective molecular risk assessment tied to diagnostic evaluation and treatment planning for MDD. A phlebotomy draw of whole blood is performed in an outpatient laboratory or clinic setting using standard venipuncture technique; the specimen is sent to the TruDiagnostic™ Inc. laboratory. The proprietary assay analyzes DNA methylation at >20,000 CpG sites and an algorithm returns a binary positive/negative risk result for MDD. Results are reviewed by the ordering clinician and incorporated into the clinical assessment, follow-up visits, and treatment discussions. Typical sites of service include outpatient mental health clinics, behavioral health centers, and ambulatory laboratory collection sites. The service type is a Proprietary Laboratory Analysis (PLA) molecular diagnostic test billed with 0622U for the TruD MDS Major Depressive Disorder assay.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation component if split billing applies and the laboratory separates technical and professional components. |